Conjunctivitis Treatment Market Size, Share & Trends Analysis Report By Disease Type (Allergic Conjunctivitis, Bacterial Conjunctivitis, Viral Conjunctivitis) By Formulation Type, By Region, And Segment Forecasts, 2024 - 2030

Conjunctivitis Treatment Market Trends

The global conjunctivitis treatment market size was valued at USD 4.3 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 4.6% from 2024 to 2030.Thesignificant prevalence of conjunctivitis and the widespread availability of treatment worldwide are the major driving factors driving the market growth. For instance, as per the National Library Medicine published in 2020, conjunctivitis impacts over 6 million individuals in the U.S. annually.

Public awareness plays a pivotal role in driving the conjunctivitis treatment market. As more people become educated about conjunctivitis's causes, symptoms, and contagious nature, they are more likely to seek medical treatment and preventive measures. Furthermore, public knowledge empowers individuals to take necessary precautions, such as improved hygiene, thereby contributing to the conjunctivitis treatment market growth as a proactive approach to managing and preventing the condition becomes more prevalent. In addition, the market experienced notable effects from COVID-19 during the pandemic period, primarily due to the potential increase in cases of conjunctivitis among individuals infected with the coronavirus.

Moreover, as viral or bacterial infections often cause conjunctivitis, the demand for pharmaceutical solutions, including antibiotics and antiviral medications, is consistently high.Patients and healthcare providers seek these pharmaceutical interventions to alleviate symptoms and reduce the condition's contagious nature. Thus, due to the high demand for improved treatment solutions, pharmaceutical companies are investing significantly in developing more effective treatment alternatives. For instance, in March 2022, Visus Therapeutics Inc. revealed the initiation of its initial phase 3 trials, namely BRIO-I and BRIO-II, for their primary product, BRIMOCHOL PF, an ophthalmic solution devoid of preservatives, designed for the treatment of presbyopia.

Disease type Insights

On the basis of drug type, the market is segmented into allergic conjunctivitis, bacterial conjunctivitis, and viral conjunctivitis. The allergic conjunctivitis segment held the largest market share in 2023 due to its high prevalence and the recurring nature of allergic reactions. Allergic conjunctivitis can be triggered by various allergens such as pollen, dust, or pet dander, making it a common condition. Furthermore, the increasing incidence of environmental allergens and heightened awareness of allergies contribute to the dominance of allergic conjunctivitis in the market as more individuals seek relief and effective management strategies for their eye allergy symptoms.

Formulations Type Insights

Based on the mode of administration, the market is segmented into ointment, drops, and drugs. The ointment segment dominated the market in 2023 due to its effectiveness in providing sustained relief and ensuring prolonged contact with the eye's surface.Ointments are particularly favored for treating conjunctivitis because they create a protective barrier over the affected area, which helps in retaining the medication and prolonging its action.

This is especially crucial for individuals with conjunctivitis, as it ensures that the treatment remains in contact with the eye's surface, allowing for consistent and thorough management of the condition. On the other hand, the drugs are expected to witness lucrative growth over the forecast period as they are the primary means of directly addressing the underlying causes and symptoms of conjunctivitis.

Regional Insights

North America dominated the market in 2023. The region has a high prevalence of conjunctivitis due to factors like environmental allergens and urbanization. Additionally, North America possesses advanced healthcare infrastructure and a robust pharmaceutical industry, enabling rapid development and availability of a wide range of treatment options. Moreover, increasing awareness among the population about eye health and the availability of various treatment options further drives the market growth. On the other hand, Asia Pacific is expected to witness lucrative growth over the forecast period. The rising healthcare infrastructure, increasing access to healthcare services, and growing pharmaceutical industry in the region have led to enhanced treatment availability and affordability, thereby contributing to the market growth in the region.

Competitive Insights

Key players operating in the market are Alembic Pharmaceuticals, Novartis AG, Sanofi SA, Bausch & Lomb Incorporated, Allergan PLC, NicOx SA, Sirion Therapeutics Inc, Pfizer Inc., and Santen Pharmaceuticals Co. Ltd. The market participants are constantly working towards new product development, M&A activities, and other strategic alliances to gain new market avenues.

In May 2022, Santen Pharmaceutical's legal entity was granted approval by the National Medical Products Administration (NMPA) in China to use Verkazia for the treatment of severe vernal keratoconjunctivitis (VKC) in children and adolescents aged four years and older.